“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years,” John Rother, president of the National Coalition on Health Care, said in a statement.
“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”
As complaints grow about exorbitant drug prices, pharmaceutical companies are coming under pressure to disclose the development costs and profits of those medicines and the rationale for charging what they do.
Amid the growing clamor, cancer medication has drawn particular ire. The average price of new cancer drugs in the U.S. increased five- to tenfold over 15 years, to more than $100,000 a year in 2012, according to the Mayo Clinic journal editorial.
In recent years, increasingly specialized medications and an aging population that takes more drugs have substantially boosted the price of treatments for cancer, hepatitis C, cystic fibrosis and other diseases.
A new PricewaterhouseCoopers report on medical cost trends highlights how specialty drugs are outpacing traditional drugs in a major way.
The rising cost of specialty drugs to treat complex, chronic or life-threatening conditions has the potential to break the pocket books of businesses, consumers, insurance companies and the state, according to Milam Ford of Blue Cross and Blue Shield of Louisiana.
We need to make clear that monopoly grants come with responsibility and accountability, and that competition is more important to the public than a blank check for innovation we cannot afford.
John Rother, President of the National Coalition on Health Care and Chair of the Campaign for Sustainable Rx Pricing issued the following statement in response to a recent health tracking poll by the Kaiser Family Foundation that found that an overwhelming 76% of Americans blame pharmaceutical companies for the rising cost of medicines.
Sophisticated drugs are opening the door, scientists say, to an era of “precision medicine.” They’re also ushering in an age of astronomical prices.